EQUASENS: results of the votes on the resolutions submitted to the ordinary annual shareholders' meeting of 29 june 2023
July 05, 2023 at 05:01 pm
Share
Villers-lès-Nancy, 5 July 2023 - 6:00 p.m. (CET)
PRESS RELEASE
RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING
OF 29 JUNE 2023
Number of shares comprising the share capital: 15,174,125
Number of shares with voting rights: 15,032,834
Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,046,120
That means a quorum of 86.78% of the 15,032,834 shares with voting rights:the Ordinary Annual General Meeting was able to deliberate.
The Ordinary Annual General Meeting was held on Thursday, 29 June 2023 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2022 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:
Resolutions
Results of the votes
RESOLUTION ONE
Approval of the annual financial statements
Resolution adopted by:
13,044,237 votes in favour
0 vote against
1,883 abstentions
RESOLUTION TWO
Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement
Resolution adopted by:
12,943,792 votes in favour
100,445 votes against
1,883 abstentions
RESOLUTION THREE Approval of the consolidated financial statements
Resolution adopted by:
13,044,237 votes in favour
0 vote against
1,883 abstentions
RESOLUTION FOUR
Appropriation of earnings, setting the dividend
Resolution adopted by:
13,046,120 votes in favour
0 vote against
0 abstention
RESOLUTION FIVE
Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code
Resolution adopted by (*):
12,983,939 votes in favour
62,072 votes against
99 abstentions
RESOLUTION SIX
Renewal of Ms. Anne LHOTE's term of office as Director
Resolution adopted by:
10,706,967 votes in favour
2,339,153 votes against
0 abstention
RESOLUTION SEVEN
Renewal of Ms. Céline GRIS's term of office as Independant Director
Resolution adopted by:
11,112,739 votes in favour
1,933,381 votes against
0 abstention
RESOLUTION EIGHT
Renewal of Ms. Émilie LECOMTE's term of office as Director
Resolution adopted by:
10,723,209 votes in favour
2,322,911 votes against
0 abstention
RESOLUTION NINE
Appointment of a new Director
Resolution adopted by:
12,902,756 votes in favour
143,364 votes against
0 abstention
RESOLUTION TEN
Appointment of a new Statutory Auditor
Resolution adopted by:
13,040,577 votes in favour
5,543 votes against
0 abstention
RESOLUTION ELEVEN
Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2022 and mentioned in Article L. 22-10-9 of the French Commercial Code
Resolution adopted by:
12,095,451 votes in favour
950,669 votes against
0 abstention
RESOLUTION TWELVE
Approval of the components of compensation paid in 2022 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors
Resolution adopted by:
13,033,420 votes in favour
12,700 votes against
0 abstention
RESOLUTION THIRTEEN
Approval of the components of compensation paid in 2022 to Mr. Dominique PAUTRAT, Chief Executive Officer
Resolution adopted by:
10,746,386 votes in favour
2,299,734 votes against
0 abstention
RESOLUTION FOURTEEN
Approval of the components of compensation paid in 2022 to Mr. Denis SUPPLISSON, Deputy Chief Executive Officer and then Chief Executive Officer
Resolution adopted by:
10,592,005 votes in favour
2,454,115 votes against
0 abstention
RESOLUTION FIFTEEN
Approval of the components of compensation paid in 2022 to Mr. Grégoire DE ROTALIER, Deputy CEO
Resolution adopted by:
10,592,005 votes in favour
2,454,115 votes against
0 abstention
RESOLUTION SIXTEEN
Approval of the compensation policy for the Chairman of the Board of Directors for 2023
Resolution adopted by:
13,033,420 votes in favour
12,700 votes against
0 abstention
RESOLUTION SEVENTEEN
Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2023
Resolution adopted by:
10,759,416 votes in favour
2,286,704 votes against
0 abstention
RESOLUTION EIGHTEEN
Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2023
Resolution adopted by:
10,759,416 votes in favour
2,286,704 votes against
0 abstention
RESOLUTION NINETEEN
Approval of the compensation policy for Directors
Resolution adopted by:
13,044,420 votes in favour
1,700 votes against
0 abstention
RESOLUTION TWENTY
Setting total annual compensation for Directors for 2023
Resolution adopted by:
13,044,420 votes in favour
1,700 votes against
0 abstention
RESOLUTION TWENTY-ONE
Authorisation by the Company to repurchase its own shares
Resolution adopted by:
11,101,214 votes in favour
1,944,906 vote against
0 abstention
RESOLUTION TWENTY-TWO
Powers for formalities
Resolution adopted by:
13,046,120 votes in favour
0 vote against
0 abstention
(*) After deduction of excluded voting rights
Financial Calendar:
Publication of H1 2023 Revenue: 3 August 2023, after French market closure.
AboutGroup Equasens
Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.
Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.
And reflecting the spirit of its tagline " technology for a more human experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.
Listed on Euronext Paris™ - Compartment A
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable Included in the Euronext Tech Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME) ISIN: FR 0012882389 – Ticker Code: EQS
Get all the news about the Equasens Group www.equasens.comand onLinkedIn
CONTACTS
Analyst and Investor Relations: Chief Administrative and Financial Officer: Frédérique SCHMIDT Tel. +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Equasens is No. 1 in France for publishing and integrating software programs for pharmacies, hospitals, healthcare facilities, laboratories, retirement homes and healthcare professionals. Net sales break down by activity as follows:
- pharmacy software publishing and integration (74%): software programs for managing data bases, information, inventories, orders, electronic care records, etc.;
- publishing of IT solutions for health and medical/social establishments (14.2%): publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, billing, receipt and accounting management, care management, supply management, etc.);
- development of solutions and infrastructures for e-Health (11.8%): digital communication, telemedicine and telehealth solutions. The group also offers financing solutions for leased goods (Nanceo).
Net sales are distributed geographically as follows: France (89.7%), Italy (5.4%), Belgium (2.9%), Germany (1%), the United Kingdom (0.8%) and Ireland (0.2%).